Patients in Indiana can be injured by the care they receive in two very different ways. Sometimes a doctor, nurse or hospital makes a mistake in diagnosis or treatment. Other times the problem lies in a prescription drug itself, and the question becomes whether its manufacturer adequately warned patients and physicians about the risks. Both situations involve medical harm, yet the legal paths they follow have almost nothing in common. This article explains how Indiana handles malpractice claims against health care providers, how nationwide drug litigation works, and why the distinction matters for anyone trying to understand their options.
The Rise of GLP-1 Drug Claims
Prescription drugs in the GLP-1 receptor agonist class, originally developed for type 2 diabetes, are now widely prescribed for weight loss as well. The group includes semaglutide products such as Ozempic and Wegovy and tirzepatide products such as Mounjaro and Zepbound. Indiana has a particular connection to this class of drugs, since Eli Lilly, the maker of Mounjaro, is headquartered in Indianapolis.
Thousands of lawsuits now allege that these medications caused serious gastrointestinal injuries, including gastroparesis, sometimes described as stomach paralysis, as well as ileus and bowel obstruction. People looking into a mounjaro lawsuit will find that federal cases alleging these injuries have been consolidated in multidistrict litigation, MDL No. 3094, in the U.S. District Court for the Eastern District of Pennsylvania. A separate MDL, No. 3163, was created for claims alleging a form of sudden vision loss called non-arteritic anterior ischemic optic neuropathy, or NAION.
How an MDL Differs From a Class Action
An MDL differs from a class action in an important way. Each plaintiff keeps an individual lawsuit, and the cases are grouped before one federal judge for pretrial matters such as discovery and expert testimony. Bellwether trials, in which a small number of representative cases go to trial first, often help both sides understand how juries might view the evidence. Individual claims can still be resolved separately, and each one depends on the plaintiff’s own medical records, prescription history and diagnosis.
The central allegations in the GLP-1 litigation focus on warnings. Plaintiffs claim the manufacturers did not adequately inform doctors and patients about the risk of severe or persistent gastrointestinal complications. The manufacturers dispute those claims. Because the litigation is still developing, the strength of any individual case depends heavily on documentation, including records showing when the drug was prescribed, when symptoms began and how the condition was diagnosed.
Why the Diagnosis Matters
Gastroparesis is commonly confirmed with a gastric emptying study, a test that measures how quickly food leaves the stomach, and the way a diagnosis was reached has become an important issue in the litigation. Symptoms such as nausea, vomiting and abdominal pain are common side effects of GLP-1 drugs, so records that document testing, specialist visits, emergency treatment or hospitalization carry far more weight than notes describing general discomfort. For vision loss claims, an ophthalmologist’s diagnosis and the timing of symptoms relative to the medication become the central questions.
Patients should not stop a prescribed medication on their own because of a lawsuit or news report. Any change in treatment is a medical decision for the prescribing physician, and continuing medical care also creates the record that any later claim would need.
Indiana’s Medical Malpractice Act
Claims against doctors, hospitals and other health care providers follow a different structure in Indiana. The state’s Medical Malpractice Act applies to qualified providers, those who carry required malpractice insurance and pay into the state’s Patient’s Compensation Fund. For most claims above a set dollar amount, a patient must first present the proposed complaint to the Indiana Department of Insurance, and a medical review panel of three physicians issues an opinion on whether the provider met the standard of care before the case can proceed in court.
The panel’s opinion is not binding, but it can be admitted as evidence at trial, and it often shapes how both sides view the claim. Families considering medical malpractice lawyers indianapolis indiana residents have used should expect the panel process to add months to the timeline before a lawsuit can be filed in court.
Caps and Deadlines
Indiana limits total damages in medical malpractice cases. For acts of malpractice occurring after June 30, 2019, the total recovery is capped at $1.8 million. A qualified provider is responsible for the first portion of that amount, currently up to $500,000, and the Patient’s Compensation Fund pays the remainder up to the cap. The cap applies to all damages combined, including medical expenses and lost earnings, which sets Indiana apart from states that cap only noneconomic damages.
Here’s the kicker, though. The panel process and the cap do not apply to every provider. A provider that has not qualified under the Act by carrying the required insurance and paying the surcharge into the fund falls outside its protections, so the claim proceeds as an ordinary negligence case without the panel requirement or the cap. Confirming a provider’s qualified status with the Department of Insurance is one of the first steps in evaluating a claim.
The filing deadline is also strict. Indiana generally requires a malpractice claim to be filed within two years of the act or omission, measured from the date of the malpractice and not from the date it was discovered, although courts have recognized limited exceptions when a patient could not reasonably have discovered the injury in time. That occurrence-based rule makes early review of a suspected medical error especially important.
Where the Two Paths Meet
Some cases involve both a drug and a provider. A patient who developed serious complications after being prescribed a medication at an inappropriate dose, or without monitoring for known side effects, may raise questions about the prescribing physician’s care as well as the drug’s warnings. Sorting out which theory applies, and against whom, affects which rules govern the claim, which court hears it, and whether the malpractice cap and panel process apply at all. When malpractice leads to a death, the resulting wrongful death claim against a qualified provider also runs through the Act, including the review panel and the overall damages cap.
Product liability claims against drug manufacturers are not subject to the Medical Malpractice Act. They follow Indiana’s product liability statute when brought in state court, or the procedures of the federal MDL when consolidated there. Indiana’s product liability law generally requires claims to be filed within two years after the cause of action accrues, with an outer limit tied to when the product was first delivered to a user, subject to certain exceptions.
Many Indianapolis firms handle a mix of injury work across these categories. Among them, Cohen & Malad handles truck accident claims along with its medical and pharmaceutical work, and injury practices of that kind often see how medical records drive every type of case, whether the injury came from a collision, a hospital or a prescription.
Records are where every medical injury claim starts. Pharmacy printouts, clinic notes and hospital discharge summaries often tell the story more clearly than any memory can, and gathering them early preserves options that may otherwise close without warning.
